Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Trial of Liposomal Daunorubicin and SU5416 in Refractory Hematologic Cancers
NCT00005942Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2000
- Primary completion
- Dec 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of semaxanib in acute myeloid leukemia (AML), myelodysplastic syndrome, refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T) and 1 more, sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 2 months and Complete Remission up to 1 year. Started Mar 2000; status: completed.
02
Drugs
semaxanib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome, refractory anemia with excess blasts (RAEB)refractory anemia with excess blasts in transformation (RAEB-T)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT00005942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005942.